STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
--Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously ...
Stocktwits on MSN
Why did GLSI stock surge 25% today?
During this period, insiders will be restricted from selling their shares unless the board decides otherwise. ・The lock-up helps align insiders with long-term shareholders while supporting the Phase ...
The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Detailed price information for Greenwich Lifesciences Inc (GLSI-Q) from The Globe and Mail including charting and trades.
(RTTNews) - Shares of Greenwich LifeSciences Inc. (GLSI) have been on a tear over the past ten days as the clinical-stage biotech pushes ahead with its financing strategy and prepares to implement ...
Sep. 18, 2025 6:00 AM ETGreenwich LifeSciences, Inc. (GLSI) CEO Snehal Patel commented, "We have visited St. Vincent's multiple times over the past few years, once to present GP2 and FLAMINGO-01 at ...
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback